Acute Polymyositis/systemic Lupus Erythematosus Overlap Syndrome with Severe Subcutaneous Edema and Interstitial Lung Disease

U-ram Jin1, Kyu-Sung Kwack2, Kyung-Joo Park2, Ji-Eun Kwon3, Si-Yeon Kim1, Ki-Chan Kim1, Ga-Yong Ban1, Ju-Yang Jung1, Chang-Hee Suh1, Hyoun-Ah Kim1

Departments of Rheumatology1, Radiology2, Pathology3, Ajou University School of Medicine, Suwon, Korea

Inflammatory myopathy is characterized by symmetrical proximal muscle weakness, elevated muscle enzyme levels and favorable response to glucocorticoids therapy. Although periorbital edema is a common manifestation of inflammatory myopathy, generalized subcutaneous edema is very rare. We report here a case of a 47-year-old female patient with acute polymyositis/systemic lupus erythematosus overlap syndrome with generalized subcutaneous edema and interstitial lung disease. We aggressively treated the disease with high-dose glucocorticoids, intravenous immunoglobulin, and immunosuppressive agents.

Key Words. Inflammatory myopathy, Overlap syndrome, Subcutaneous edema, Interstitial lung disease

Introduction

Inflammatory myopathy is usually characterized by inflammation of proximal muscle, which results in muscle weakness and elevated muscle enzyme levels. As the disease progresses, esophageal and respiratory muscles may be affected. Other manifestations, such as skin lesions, arthritis, calcinosis, vasculitis and interstitial lung disease are relatively common (1,2).

Periorbital edema is not an uncommon manifestation of the disease, but generalized edema is rarely reported (3-13). There are no guidelines for the treatment of this condition and the clinical courses of reported cases have been variable.

We describe a case of polymyositis/systemic lupus erythematosus (SLE) overlap syndrome with severe generalized subcutaneous edema and interstitial lung disease. Magnetic resonance imaging (MRI) presented myositis and generalized edema, and chest computed tomography (CT) scan presented interstitial lung disease. The patient was treated successfully with corticosteroid, human intravenous immunoglobulin (IVIg), and immunosuppressive agents.

Case Report

A 47-year-old woman was admitted with progressive proximal muscle weakness, generalized swelling, fever, dysphagia, and dyspnea for 7 days. She had no history of diabetes mellitus, hypertension, or pulmonary tuberculosis, but had a 2-month history of rheumatoid arthritis. She was treated with hydroxychloroquine and nonsteroidal anti-inflammatory drug. She had cancer screening including esophagogastroduodenoscopy and colonoscopy about 1 month ago, and no evidence was found of an underlying malignancy. Examination revealed a blood pressure of 130/64 mmHg, pulse rate of 105/min, respiratory rate of 20/min, and body temperature of 37.6℃. A physical examination revealed generalized nonpitting edema on face, trunk, upper and lower extremities including hands and feet (Figure 1). Fine crackles were noted bilaterally on auscultation of the lungs. She had no tender and swollen joints. A musculoskeletal examination showed decreased muscle power in her shoulder and pelvic girdles with a Medical Research Council (MRC) scale score 4. She had no Raynaud’s phenomenon, Gottron papules, heliotropic rash, “V” sign on her neck, or shawl sign.
Her initial laboratory findings showed; white blood cell 11,000/mm³, hemoglobin 11.2 g/dL, platelet 221,000/mm³, erythrocyte sedimentation rate (ESR) 103 mm/hr, and C-reactive protein (CRP) 6.91 mg/dL. The muscle enzymes were elevated: creatine kinase (CK) 12,176 U/L (normal 29 ~ 145 U/L), myoglobin >3,000 ng/mL (normal 0 ~ 51 ng/mL), aldolase 47.4 U/L (normal 0 ~ 7.6 U/L), aspartate aminotransferase 565 U/L, alanine aminotransferase 374 U/L, and lactate dehydrogenase 1,597 U/L (normal 100 ~ 200 U/L). Antinuclear antibody (ANA) was positive (1 : 2,560, speckled and cytoplasmic mixed pattern), and complement 3 was reduced (C3 52 mg/dL, C4 13 mg/dL). Anti-Jo-1 antibody, anti-Ro antibody, anti-La antibody, anti-double stranded DNA antibody, and anti-cardiolipin antibody were all negative. However, anti-Sm antibody and anti-RNP antibody were positive, and rheumatoid factor and anti-cyclic citrullinated peptide antibody were elevated with 83.6 IU/mL and 43 U/mL. She had subclinical hypothyroidism with TSH level 12.34 µIU/mL, T3 60.4 ng/dL and free T4 0.72 ng/dL. Chest radiography showed infiltrates at both lower lung zone. A CT scan of the chest showed interstitial lung disease with ground glass opacity and air space consolidation, bilateral pleural effusion, and minimal pericardial effusion (Figure 2). Electrocardiography was unremarkable and echocardiography revealed small amount of pericardial effusion. She tried to undergo pulmonary function test, but failed due to respiratory difficulty. MRI of the lower extremities showed increased signal intensity in the muscle layer and extensive fluid collection in the adjacent subcutaneous layer, which was compatible with subcutaneous and muscular edema (Figure 3). The electromyographic findings were consistent with the inflammatory myopathy. A muscle biopsy was performed from the deltoid muscle of left arm. Histological examination revealed that inflammatory cell infiltrates to perimysial area and perifascicular atrophy (Figure 4). Furthermore, she was diagnosed as SLE on the basis of ANA, anti-Sm antibody, hypocomplementemia, and serositis. These findings were compatible with acute polymyositis/SLE overlap syndrome with generalized subcutaneous edema and interstitial lung disease.

The patient was treated with high-dose prednisolone (1 mg/kg). However, her muscle weakness and generalized subcutaneous edema were not improved, the fever was sustained and her respiratory difficulty was aggravated with increased pleural effusion at right lung. She underwent thoracentesis with 650 mL of pleural fluid drainage. The pleural fluid was compatible for transudates. As the clinical feature was highly suggestive of edematous polymyositis refractory to high-dose prednisolone, the patient was treated with pulse methylprednisolone (1.0 g per day) intravenously for 3 days, followed by high-dose prednisolone (1 mg/kg) and azathioprine (100 mg per day). Then the generalized edema gradually decreased with a concomitant increase in muscular strength, and the fever was subsided, but muscle weakness and generalized edema were persistent despite the treatment with pulse methylprednisolone. Furthermore, the patient presented with flushing and skin rashes after treatment with azathioprine. Therefore, treatment with azathioprine had stopped, and the patient was treated with human IVIg at a dose of 400 mg/day for 5 days, which resulted in improvement in her muscle weakness and generalized edema along with decreased muscle enzyme levels with creatine kinase 4,699 IU/L. Although there were somewhat improvement, muscle weakness, generalized edema, and elevated muscle enzyme levels were persistent. So, the patient was again treated with human
Figure 2. Radiologic findings of computed tomography (CT) scan of the chest. (A) The CT scan of the chest upon admission shows interstitial lung disease with consolidation and ground-glass opacities in peripheral lungs, bilateral pleural effusion, and minimal pericardial effusion. (B) The resolution of the interstitial lung disease after treatment.

Figure 3. Radiologic findings of magnetic resonance imaging (MRI) of the thigh. (A) Axial T1-weighted image only shows generalized subcutaneous edema with focal low-signal subcutaneous fluid adjacent to vastus lateralis muscle (arrows). (B) Axial fat-suppressed fast spin-echo T2-weighted image shows a pattern of patchy elevated signal within multiple muscles in all three compartments. Biceps femoris, semimembranosus, and adductor magnus are relatively spared. (C) Axial fat-suppressed contrast-enhanced T1-weighted image shows a similar pattern of elevated signal within the affected muscles similar to the distribution seen on T2-weighted images. There is patchy enhancement of the quadriceps femoris group, sartorius, gracilis, and semitendinosus muscles (arrows).
IVIg at a dose of 400 mg/day for 5 days, which resulted in significant improvement in her muscle strength with an MRC scale score 5, improved generalized edema, and decreased muscle enzyme levels with creatine kinase 1,447 IU/L, and then treatment with tacrolimus (1 mg per day) had started. A CT scan of the chest was followed up and it revealed improved interstitial lung disease in both lungs with decreased extent of consolidation and residual ground glass opacity (Figure 2). The patient was discharged on the 58th hospital day with oral prednisolone (40 mg/day) and tacrolimus. At 6 months follow-up, musculoskeletal examination showed normal muscle power on both upper and lower extremities without generalized subcutaneous edema and laboratory test showed ESR 45 mm/hr, CRP 0.28 mg/dL, CK 175 U/L, aldolase 6.7 U/L, C3 105 mg/dL and C4 39 mg/dL with prednisolone (12.5 mg/day) and tacrolimus (2 mg/day).

**Discussion**

This case had polymyositis/SLE overlap syndrome associated with generalized subcutaneous edema and interstitial lung disease. The clinical, laboratory, image, and biopsy findings in this case were all compatible with polymyositis associated with SLE. Non-pitting edema involved the face, trunk, and upper and lower extremities. Other conditions causing the edema were excluded (e.g., congestive heart failure, renal failure and liver cirrhosis). She had subclinical hypothyroidism and her TSH level was 12.34 uIU/mL, but it did not seem to be the cause of generalized edema because her T3 and free T4 levels were in reference range.

Some patients with inflammatory myositis also meet the criteria for one of the connective tissue disorders (14). Connective tissue disorders include rheumatoid arthritis, scleroderma, SLE, Sjögren’s syndrome and mixed connective tissue disease, and of all the connective tissue disorders, inflammatory myositis overlaps with scleroderma commonly. These patients may have polyarthritis, sclerodactyly, Raynaud’s phenomenon and symptoms of myositis. Also, these patients could have non-myositis-associated antibodies including ANA, PM-Scl and Ku antibodies. Our patient was diagnosed an overlap with SLE as defined by the clinical and laboratory features, and had ANA, anti-Sm, and anti-RNP antibody.

The association between inflammatory myopathy and generalized subcutaneous edema is extremely rare (3-13). Affected patients usually had highly active diseases, with pronounced muscle weakness and sometimes with esophageal involvement. Of these cases, two cases were associated with malignancy: esophageal cancer and cervical cancer (10,13). The pathophysiology of generalized edema in inflammatory myopathy is unclear. The authors of previous reports had suggested that perivascular inflammation and endothelial damage through the autoimmune process may result in increased capillary permeability (3-5,7). Two cases were spontaneously recovered without any specific treatment (7,10). Six cases of active disease had esophageal involvement, and three of them died from respiratory failure despite of aggressive treatment (5,12). Initially, treatment with glucocorticoids can improve the degree of generalized edema and was used in most reported cases (3-8,11,12). Second-line treatments, including azathioprine, methotrexate and human IVIg were considered in purpose of steroid-sparing effect or in the severe cases (4,5,7,8,12). Human IVIg is used as an alternative to azathioprine or methotrexate in inflammatory myopathy: some myositis experts suggested that when beginning therapy in severely affected patients or in rapidly progressive disease with high doses of prolonged corticosteroids, human IVIg was preferred (15). In our case, the generalized edema was not well controlled by glucocorticoid therapy including high-dose oral prednisolone and intravenous pulse methylprednisolone, but responded to treatment with human IVIg. With decreased generalized edema, muscle weakness, dysphagia, and interstitial lung disease were improved. She had drug eruption of azathioprine, so we used oral prednisolone and tacrolimus for maintenance therapy.

Generalized subcutaneous edema could be an initial manifestation of inflammatory myopathies and is usually presenting in patients with very active disease course (5,11). In our case, a generalized subcutaneous edema is one of initial manifestations of inflammatory myopathy, and active and severe dis-
ease course including esophageal and respiratory involvement were shown. Although there are few case reports of this condition, the prognosis of this disease seems to be usually favorable. But in some cases, it may have a fatal course, especially when the patient has esophageal and respiratory involvement (5, 12). Recent studies reported favorable clinical and biochemical response after treatment with rituximab in refractory inflammatory myopathy (15). So treatment with rituximab may be helpful in refractory inflammatory myopathy with generalized edema, especially involving esophageal and respiratory muscle (4).

**Summary**

We report a rare patient with polymyositis/SLE overlap syndrome associated with generalized subcutaneous edema. Her muscle power and edema were much improved after the third course of IVIg and maintenance therapy of tacrolimus. IVIg was an effective treatment in this case.

**References**